TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting

Monday, December 7, 2009 General News
Email Print This Page Comment bookmark
Font : A-A+

TAIPEI, Taiwan, Dec. 7 TaiGen Biotechnology Co., Ltd.announced today the presentation of Phase I and preclinical data for TG-0054,the Company's chemokine receptor CXCR4 antagonist and a novel, potent stemcell mobilizer, at the ASH Annual Meeting held in New Orleans, the US, fromDecember 5 to 8, 2009.

The clinical data of Phase 1 study will be presented. In this randomized,double-blind, placebo-controlled, sequential ascending single intravenous dosestudy, TG-0054 exhibited excellent and favorable safety, tolerability,pharmacokinetics (PK), and pharmacodynamics (PD) profile. A maximallytolerated dose (MTD) was established. Good tolerability was observed. PKparameters showed dose proportionality over the dose range studied. PD resultsshowed potent, dose-dependent mobilization of CD34+ hematopoietic stem cellsand CD133+ endothelial progenitor cells into peripheral blood circulation.

The preclinical data will be reported on in vitro assays and in vivostudies in mouse models. TG-0054 demonstrated potent and selectiveantagonistic activities against CXCR4 in vitro. Significant mobilization ofCD34+ hematopoietic stem cells and CD133+ endothelial progenitor cells wasobserved when TG-0054 was used alone or combined with G-CSF in preclinicalmodels.

The preclinical and Phase I results support further clinicalinvestigation. The Phase 2 study entitled "A Phase II, Randomized, Open-Label,Multi-Center Study to Evaluate the Safety, Pharmacokinetics, and HematopoieticStem Cell Mobilization of TG-0054 in Patients with Multiple Myeloma,Non-Hodgkin Lymphoma or Hodgkin Disease" will begin to enroll patients inDecember, 2009.

About TaiGen Biotechnology

TaiGen Biotechnology ( http://www.taigenbiotech.com/ ) is a leadingdevelopment stage pharmaceutical company based in Taiwan with a wholly-ownedsubsidiary in Beijing, China. The company has a full capacity in discoveryresearch and clinical development in China/Taiwan/US. Its current pipelineincludes therapeutics for infectious diseases, diabetic complications andcancer for the worldwide market. In addition to TG-0054, Nemonoxacin, a novelbroad-spectrum non-fluorinated quinolone with anti-MRSA activity andin-licensed from P&G Pharmaceuticals, achieved non-inferiority in clinicalcure rate and safety profile compared with Levofloxacin in its Phase II CAPtrial. The company has completed a second phase II study in diabetic footinfection to demonstrate Nemonoxacin's anti-MRSA activity with once-a-day oraldosing. TaiGen is seeking Nemonoxacin licensees for the US, EU and Japanmarkets. TaiGen also has HCV protease inhibitors in advanced preclinicalprograms to treat chronic hepatitis C infection.ASH 2009 Meeting Presentation: Clinical Oral presentation: TG-0054, a Novel and Potent Stem Cell Mobilizer, Displays Excellent PK/PD and Safety Profile in Phase 1 Trial Tuesday, December 8, 2009: 7:30 AM-9:00 AM Preclinical Poster: Rapid Mobilization of Murine Hematopoietic Stem and Progenitor Cells with TG-0054, a Novel CXCR4 Antagonist (Poster Board number: III-479) Monday, December 7, 2009: 6:00 PM-8:00 PM

SOURCE TaiGen Biotechnology Co., Ltd.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store